Tyrosine kinase inhibitors (TKIs) targeting VEGFR and MET, including pazopanib, sunitinib, and cediranib, have demonstrated encouraging results in advanced ASPS, frequently resulting in disease stabilization or partial responses (2, 3). Here, KDR is linked to alveolar soft part sarcoma.